DMT310-009 Topical in the Treatment of Acne Vulgaris - Trial NCT06090721
Access comprehensive clinical trial information for NCT06090721 through Pure Global AI's free database. This Phase 3 trial is sponsored by Dermata Therapeutics and is currently Not yet recruiting. The study focuses on Acne Vulgaris. Target enrollment is 555 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Dermata Therapeutics
Timeline & Enrollment
Phase 3
Oct 01, 2023
Oct 01, 2024
Primary Outcome
Efficacy as measured by lesion counts,Efficacy as measured by Investigator Global Assessment (IGA)
Summary
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder
 mixed with diluent in male and female patients with moderate to severe facial acne vulgaris
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06090721
Non-Device Trial